Related documents Search history  |  Help

Alliance for Hippocratic Medicine, et al., v. U.S. Food and Drug Administration, et al., v. Danco Laboratories, LLC; Opinion (No. 23-10362, restoring U.S. Food and Drug Administration's mifepristone approval but upholding lower court's block of new FDA regulations broadening access to the drug; abortion medication). (Link Type: Federal Court Case)
See: https://lrl.texas.gov/scanned/archive/2023/52069.pdf
By U.S. Court of Appeals for the Fifth Circuit
Publication Date: August 16, 2023

Alliance for Hippocratic Medicine, et al., v. U.S. Food and Drug Administration, et al.; Memorandum opinion and order (No. 2:22-CV-00223-Z, suspending FDA's approval of mifepristone, contending the agency lacked legal authority to approve and enable access, and blocking new FDA regulations broadening access to the drug; abortion medication). (Link Type: Federal Court Case)
See: https://s3.documentcloud.org/documents/23746119/read-texas-federal-judge-ruling-on-abortion-pill.pdf
By U.S. District Court for the Northern District of Texas, Amarillo Division
Publication Date: April 7, 2023

Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine, et al., and Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al.; Opinion (Nos. 23-235 and 23-236, plaintiff's lack standing to challenge FDA's actions regarding regulation of mifepristone). (Link Type: Federal Court Case)
See: https://www.supremecourt.gov/opinions/23pdf/23-235_n7ip.pdf
By U.S. Supreme Court
Publication Date: June 13, 2024

Risk evaluation and mitigation strategy (REMS): Single shared system for mifepristone 200 mg (broadening access to abortion medication, allowing it to be prescribed by pharmacists or through a telehealth consultation and sent through the mail). (Link Type: Agency Document)
See: https://www.accessdata.fda.gov/drugsatfda_docs/rems/Mifepristone_2023_01_03_REMS_Full.pdf
By U.S. Food and Drug Administration (FDA) / Danco Laboratories, LLC
Publication Date: January 2023